Article
Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.
Current cancer drug targets - 1 May 2008
De Cicco Concetta, Ravasi Laura, Zorzino Laura, Sandri Maria Teresa, Botteri Edoardo, Verweij Fabrizio, Granchi Donatella, de Cobelli Ottavio, Paganelli Giovanni
Abstract excerpt
BACKGROUND: Prostate adenocarcinoma is generally characterized by slow progression although some phenotypes have a more aggressive behavior with tendency to local invasion and distant metastases, mainly to bones. Better specific care could be provided to the aggressive phenotype-group of patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.